The use of Cyclosporin A in acute steroid-refractory ulcerative colitis: Long term outcomes | Zendy

Lisa Sharkey | Zendy; F Bredin | Zendy; Allison Nightingale | Zendy; Miles Parkes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The use of Cyclosporin A in acute steroid-refractory ulcerative colitis: Long term outcomes

Author(s) -

Lisa Sharkey,

F Bredin,

Allison Nightingale,

Miles Parkes

Publication year - 2010

Publication title -

journal of crohn s and colitis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.277

H-Index - 80

eISSN - 1876-4479

pISSN - 1873-9946

DOI - 10.1016/j.crohns.2010.10.004

Subject(s) - medicine , ulcerative colitis , thiopurine methyltransferase , colectomy , azathioprine , adverse effect , neutropenia , tolerability , immunosuppression , population , surgery , refractory (planetary science) , maintenance therapy , gastroenterology , chemotherapy , disease , physics , environmental health , astrobiology

Approximately 15% of patients with ulcerative colitis will have a severe flare requiring hospitalisation at some stage. For those who fail to respond to intravenous steroids Cyclosporin A (CyA) therapy is one option. We have evaluated the management of such patients in our centre and present the long term colectomy avoidance rates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research